Drawing for PNEOO

USPTO serial 79407300

PNEOO

Reviewed by CopyMark Law Group

Reg. 8226523Status 700Registered
Filing date
Status date
Registration date
Apr 28, 2026
Examiner
PEISECKI, MARK A
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with PNEOO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Cheryl L. Burbach

Cheryl L. Burbach Erise IP, P.A.7015 College Blvd.Suite 700Overland Park, KS 66211

Goods and services

ClassDescriptionStatusFirst use
001Biological preparations for use in cell cultures, other than for medical or veterinary purposes, for boosting cells in the immune system for improved therapies; biological preparations for use in cell cultures, in the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents in the nature of complexes of molecules for scientific research and for clinical and industrial use; proteins for use in scientific research; regulatory proteins in raw material for scientific research; the aforementioned goods solely related to respiratory and pulmonary diseases, including lung cancerACTIVE—
005Medical, biological, and pharmaceutical preparations for the treatment of pulmonary diseases; veterinary preparations for pets, cattle, livestock for preventing and treating infectious diseases, medical disorders, and diseases, namely, lung cancer; medical, biological, and pharmaceutical preparations for preventing and treating infectious diseases, medical disorders, and diseases, namely, lung cancer; medical, biological, and pharmaceutical preparations for preventing and treating viral, bacterial, and yeast infections; veterinary preparations for pets, cattle, livestock for preventing and treating viral, bacterial, and yeast infections; medical, biological, and pharmaceutical preparations for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; veterinary preparations for pets, cattle, livestock for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines; regulatory proteins for medical use, namely, protein arrays for medical diagnosis purposes, the foregoing solely related to respiratory and pulmonary diseases, including lung cancer; pharmaceutical compounds being a component in pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for the prevention of diseases of the respiratory system; diagnostic preparations for medical purposes, the foregoing solely related to respiratory and pulmonary diseases, including lung cancer; chemical diagnostic reagents for medical use, the foregoing solely related to respiratory and pulmonary diseases, including lung cancerACTIVE—
040Provision of information, advice and consultancy services in the fields of cell therapy, gene editing, protein replacement, and antibodies, the aforementioned services solely related to respiratory and pulmonary diseases, including lung cancerACTIVE—
042Medical research services for the treatment of various medical disorders, cancer, pulmonary diseases, respiratory diseases, and infectious diseases; Scientific laboratory services; scientific research for medical purposes in the area of diseases; scientific research in the field of genetics and genetic engineering; genetic research for scientific research purposes; genetic mapping for scientific purposes; DNA screening for scientific research purposes; DNA analysis services for scientific research purposes; providing scientific research information in the field of medical disorders and their treatment; biotechnological research relating to enzymatic synthesis; toxicity testing for scientific research purposes; toxicity analysis for scientific research purposes; software as a service (SaaS) featuring artificial intelligence software for use in database management relating to the medical field; software as a service (SaaS) featuring software for use in data base management relating to the medical field; all of the aforementioned services solely related to respiratory and pulmonary diseases, including lung cancerACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 22, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 1, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Oct 1, 2026FIMPFINAL DISPOSITION PROCESSED—
Jul 28, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Apr 28, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Apr 28, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 13, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 13, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 13, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 13, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 13, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 9, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Mar 23, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 23, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Mar 10, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 10, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 5, 2026GPNXNOTIFICATION PROCESSED BY IB—
Mar 4, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 18, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Feb 17, 2026OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Feb 10, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 31, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 31, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 31, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 14, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Nov 7, 2025RFNTREFUSAL PROCESSED BY IB—
Oct 9, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 8, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 8, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 8, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 12, 2025RFNTREFUSAL PROCESSED BY IB—
Mar 28, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 27, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 27, 2025RFRRREFUSAL PROCESSED BY MPU—
Feb 21, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 20, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 13, 2025DOCKASSIGNED TO EXAMINER—
Oct 24, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 24, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 24, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance